Rezultati

eNauka >  Results >  Updated analysis and patient-reported outcomes (PROs) from CITYSCAPE: A randomised, double-blind, phase II study of the anti-TIGIT antibody tiragolumab plus atezolizumab (TA) versus placebo plus atezolizumab (PA) as first-line treatment for PD-L1+NSCLC
Title: Updated analysis and patient-reported outcomes (PROs) from CITYSCAPE: A randomised, double-blind, phase II study of the anti-TIGIT antibody tiragolumab plus atezolizumab (TA) versus placebo plus atezolizumab (PA) as first-line treatment for PD-L1+NSCLC
Authors : Cho, BC; ...; Secen, Nevena M; ...; (broj, koautora 19)
Issue Date: 2021
Publication: ANNALS OF ONCOLOGY
ISSN: 0923-7534 Annals of Oncology Search Idenfier
Type: Conference Paper
Collation: vol. 32 str. S1428-S1428
DOI: 10.1016/j.annonc.2021.10.217
WoS-ID: 000731051400120
URI: https://enauka.gov.rs/handle/123456789/823623
Metadata source: (Preuzeto iz Nasi u WoS)
M-category: 
Mp. category will be shown later

11
OpenCitations
20
WEB OF SCIENCETM
Alt metrika
Dimensions
Unpaywall

Google ScholarTM

Rezultati na eNauka su zaštićeni autorskim pravima i sva prava su zadržana, osim ako nije drugačije naznačeno.